Apogee Therapeutics CMO Dambkowski sells $737k in stock

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 5,500 shares of the company's common stock on August 5, 2026. The transaction, executed under a pre-arranged Rule 10b5-1 trading plan, yielded a total value of $737,934. The shares were sold at $134.17 each, coinciding with the stock's proximity to its 52-week high of $134.88.

Notably, the stock had appreciated by 261% over the past year. Despite the sale, Dambkowski further increased his stake in the company by acquiring an additional 4,125 shares through the exercise of stock options on the same day, totaling $94,297. These options were part of a broader grant, entitling him to purchase 175,345 shares and vesting in forty-eight equal monthly installments.

Following the sale, Dambkowski directly owns 168,498 shares and holds 110,665 stock options. Concurrently, Apogee Therapeutics shareholders voted to approve the company's acquisition by AbbVie, valuing the firm at $10.9 billion or $135.11 per share. Analysts, including BTIG, Mizuho, and UBS, subsequently downgraded Apogee Therapeutics' stock rating to Neutral from Buy, with Mizuho raising its price target to $135 from $110.

The acquisition also prompted Apogee Therapeutics to enter into agreements with Paragon Therapeutics for the discovery and development of interleukin 31 receptor antibodies.